title: [Osteoporosis].
abstract: Bone events related to bariatric surgery remain controversial. Denosumab, used in osteoporosis treatment, is safe and efficient. Romosozumab, an antibody raised against sclerostin, is a promising bone anabolic agent. Odanacatib, a cathepsin-K inhibitor, decreases bone resorption and reduces osteoporotic fracture risk. Denosumab, as bone resorption inhibitor, and Teriparatide, as anabolic agent, have been tested together in patients with osteoporosis. Calcium supplements and cardiovascular risk are still debated. Drug holiday, after long-term treatment with bisphosphonates, is not associated with an increased fracture rate in patients with moderate risk.
authors: Brigitte
authors: B
authors: Uebelhart
authors: René
authors: R
authors: Rizzoli
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D050110:Bariatric Surgery / Q000009:adverse effects; D001713:Biphenyl Compounds / Q000627:therapeutic use; D000069448:Denosumab; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001713:Biphenyl Compounds; C557282:romosozumab; D000069448:Denosumab; C527128:odanacatib